Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adolor Corporation has announced that clinical testing will be permitted under an investigational new drug application for ADL5747, a novel oral compound that targets the delta opioid receptor. Adolor expects to initiate Phase I clinical testing in the first quarter of 2008.
Subscribe to our email newsletter
Adolor and Pfizer are collaborating on the worldwide development and commercialization of two novel delta opioid agonist compounds, ADL5859 and ADL5747, for the treatment of pain.
The delta receptor is one of three opioid receptors. Through a proprietary research platform based on cloned, human opioid receptors, Adolor has identified a series of novel, orally active delta agonists – compounds that selectively stimulate the delta opioid receptor. The company said that delta compounds may have a number of potential advantages, including an improved side effect profile, as compared to mu opioid receptor agonists.